TD Cowen initiated coverage of Prime Medicine with a Buy rating. Prime Medicine is developing its prime editing platform that can be used to make precise genetic modifications with potentially improved efficacy and safety compared to first generation technologies, says the analyst. Prime’s lead asset is PM359 for the treatment of chronic granulomatous disease, or CGD, which is expected to enter the clinic this year and see first human data in 2025, noted the analyst.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRME:
- Prime Medicine started with Outperform on ‘differentiated’ platform at Wedbush
- Prime Medicine price target lowered to $20 from $24 at Guggenheim
- Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
- Prime Medicine reports FY23 EPS ($2.18), consensus ($1.97)
- Prime Medicine to Participate in Upcoming Investor Conferences
